Terns Pharmaceuticals Inc (TERN) concluded trading on Wednesday at a closing price of $4.18, with 2.68 million shares of worth about $11.2 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -49.82% during that period and on January 29, 2025 the price saw a loss of about -6.28%. Currently the company’s common shares owned by public are about 84.92M shares, out of which, 62.32M shares are available for trading.
Stock saw a price change of -10.49% in past 5 days and over the past one month there was a price change of -28.91%. Year-to-date (YTD), TERN shares are showing a performance of -24.55% which decreased to -21.87% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $4.32 but also hit the highest price of $11.40 during that period. The average intraday trading volume for Terns Pharmaceuticals Inc shares is 1.71 million. The stock is currently trading -15.08% below its 20-day simple moving average (SMA20), while that difference is down -26.68% for SMA50 and it goes to -39.28% lower than SMA200.
Terns Pharmaceuticals Inc (NASDAQ: TERN) currently have 84.92M outstanding shares and institutions hold larger chunk of about 71.65% of that.
The stock has a current market capitalization of $355.05M and its 3Y-monthly beta is at -0.37. It has posted earnings per share of -$1.18 in the same period. It has Quick Ratio of 32.99 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for TERN, volatility over the week remained 6.33% while standing at 6.00% over the month.
Stock’s fiscal year EPS is expected to rise by 6.27% while it is estimated to decrease by -10.71% in next year. EPS is likely to grow at an annualized rate of -4.53% for next 5-years, compared to annual growth of -12.40% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Oppenheimer on October 31, 2024 offering an Outperform rating for the stock and assigned a target price of $82 to it. Coverage by Mizuho stated Terns Pharmaceuticals Inc (TERN) stock as a Buy in their note to investors on June 22, 2023, suggesting a price target of $16 for the stock. On June 07, 2023, Jefferies Initiated their recommendations, while on May 31, 2023, ROTH MKM Initiated their ratings for the stock with a price target of $23. Stock get an Outperform rating from BMO Capital Markets on May 08, 2023.
